Complications of IV Thrombolysis
Intravenous thrombolysis with alteplase or tenecteplase remains the cornerstone of acute ischemic stroke treatment. While the benefits of timely reperfusion are well-established, clinicians must be prepared to recognize and manage the complications that can arise. This article reviews the major complications of IV thrombolysis—hemorrhagic transformation, angioedema, cerebral edema, and others—with an emphasis on classification systems, imaging considerations, and evidence-based management protocols.
🔹 Bottom Line: Complications of IV Thrombolysis
- Symptomatic ICH (sICH): Occurs in ~2–7% of patients depending on agent and definition used; rates are generally lower with tenecteplase (0.25 mg/kg) compared to alteplase.
- Hemorrhage classification matters: Petechial hemorrhagic infarction (HI-1/HI-2) is usually benign; parenchymal hematoma type 2 (PH-2) is the clinically significant entity requiring intervention.
- When to repeat CT: Immediately for any neurological deterioration; routine imaging at 18–36 hours is standard practice, especially post-thrombectomy.
- sICH reversal protocol: Cryoprecipitate (10 U, target fibrinogen >150 mg/dL) ± tranexamic acid 1 g IV; stop any ongoing thrombolytic infusion.
- Angioedema: Risk is 3–5× higher with ACE inhibitor use; manage with airway protection, methylprednisolone, diphenhydramine, and icatibant for refractory cases.
Hemorrhagic Transformation
Overview and Incidence
Hemorrhagic transformation (HT) represents a spectrum from asymptomatic petechial bleeding to life-threatening parenchymal hematoma. The incidence varies significantly based on the definition used, with symptomatic intracranial hemorrhage (sICH) occurring in approximately 2–7% of thrombolysis-treated patients.
In the landmark NINDS trial, sICH occurred in 6.4% of alteplase-treated patients versus 0.6% with placebo. ECASS III reported sICH rates of 7.9% (alteplase) versus 3.5% (placebo) using the ECASS definition. More recent registries using the stricter SITS-MOST definition have reported lower rates of 1.7–2.4%.
Tenecteplase at 0.25 mg/kg has consistently shown comparable or lower sICH rates. In EXTEND-IA TNK, sICH was 1% in both tenecteplase and alteplase arms. The TRACE III extended-window trial reported sICH of 3.0% with tenecteplase versus 0.8% without thrombolysis, while TIMELESS found sICH rates of 3.2% (TNK) versus 2.3% (placebo) in the 4.5–24 hour window.
🔹 Clinical Relevance: Risk Factors for sICH
- Large infarct volume (low ASPECTS, extensive early ischemic changes)
- Older age (>80 years)
- Severe hypertension at presentation
- Hyperglycemia
- Cerebral microbleeds >10 on MRI (CMB burden increases risk but does not preclude treatment)
- Dual antiplatelet therapy at time of thrombolysis
- Longer onset-to-treatment time
- Prior anticoagulant use (though DOACs within therapeutic range remain a relative consideration)
Classification of Hemorrhagic Transformation
Multiple classification systems exist for post-thrombolysis hemorrhage. Understanding these definitions is critical for interpreting trial data and guiding clinical decisions. The table below compares the major systems:
| Classification | HI-1 | HI-2 | PH-1 | PH-2 | sICH Definition |
|---|---|---|---|---|---|
| NINDS | Not differentiated by subtype | Any hemorrhage on CT + clinical deterioration suggesting hemorrhage as cause | |||
| ECASS/ECASS-II | Small petechiae along infarct margins | Confluent petechiae within infarct, no mass effect | Hematoma ≤30% of infarct, mild mass effect | Hematoma >30% of infarct with significant mass effect | Any hemorrhage + NIHSS ↑ ≥4 points |
| SITS-MOST | HI (petechial) | PH (parenchymal hematoma) | PH-2 only + NIHSS ↑ ≥4 points within 22–36 h | ||
| Heidelberg | HI-1a/1b/1c by location | HI-2 confluent | PH-1 (<30%) | PH-2 (>30%) or remote PHr | Any ICH + NIHSS ↑ ≥4 or death within 24h attributable to ICH |
The SITS-MOST definition is the most clinically relevant as it focuses on PH-2 (the hemorrhage type most associated with clinical deterioration) and requires both radiographic and clinical criteria. This explains why sICH rates reported with SITS-MOST are typically lower than those using NINDS or ECASS definitions.
When to Repeat CT Head
The timing of follow-up neuroimaging after thrombolysis depends on clinical status and whether thrombectomy was performed:
- Immediate imaging: Required for any neurological deterioration (worsening NIHSS, decreased level of consciousness, new headache, vomiting, acute hypertension)
- Routine follow-up: Standard practice is non-contrast CT at 18–36 hours post-thrombolysis to assess for hemorrhagic transformation before initiating antiplatelet or anticoagulant therapy
- Post-thrombectomy considerations: Patients who undergo mechanical thrombectomy often receive contrast during the procedure. Contrast staining on CT can mimic hemorrhage, creating diagnostic uncertainty.
🔹 Clinical Relevance: Distinguishing Contrast Staining from Hemorrhage
- Dual-energy CT (DECT): Can differentiate iodine contrast from blood based on material decomposition; if available, this is the preferred modality post-thrombectomy
- MRI with gradient echo (GRE) or SWI: Blood products cause susceptibility artifact ("blooming"); contrast does not—highly reliable for differentiation
- Repeat CT at 24–48 hours: Contrast clears faster than hemorrhage; persistence or evolution of hyperdensity suggests true hemorrhage
- Hounsfield units: Though not definitive, HU >90 may suggest contrast, while hemorrhage is typically 40–80 HU acutely
Treatment of Symptomatic ICH
When sICH is suspected or confirmed, rapid intervention is essential. The 2026 AHA/ASA guidelines provide a structured approach:
🔴 Management of Post-Thrombolysis Symptomatic ICH
- Stop thrombolytic: Discontinue alteplase infusion immediately (if still running) or stop tenecteplase push
- Emergent labs: CBC, PT/INR, aPTT, fibrinogen level, type and screen
- Emergent non-contrast head CT: Confirm hemorrhage
- Cryoprecipitate: 10 units IV over 10–30 minutes; target fibrinogen ≥150 mg/dL (10 units raises fibrinogen ~50 mg/dL)
- Antifibrinolytic therapy: Tranexamic acid 1 g IV over 10 min OR aminocaproic acid 4–5 g IV over 1 hour, then 1 g/h until bleeding controlled
- Blood pressure control: Target SBP <140 mmHg per ICH guidelines
- Supportive care: ICP management, CPP optimization, temperature and glucose control
- Consultations: Hematology and neurosurgery as indicated
Importantly, the MOST trial evaluated adjunctive argatroban and eptifibatide with thrombolysis and found no benefit—in fact, argatroban was associated with higher mortality (24% vs. 8%). This underscores that augmenting thrombolysis with additional antithrombotics increases hemorrhagic risk without clinical benefit.
🔹 Clinical Relevance: When to Reverse vs. Watch
- Asymptomatic petechial hemorrhage (HI-1, HI-2): Generally benign; no reversal needed. Monitor clinically, hold antithrombotics, repeat imaging in 24 hours.
- Symptomatic PH-2: Aggressive reversal with cryoprecipitate and antifibrinolytics; consider neurosurgical consultation for evacuation if accessible location and clinical decline.
- Remote parenchymal hemorrhage (PHr): Treat as symptomatic ICH if causing neurological deterioration.
- Extraischemic hemorrhage: Though rare, may occur in patients with underlying amyloid angiopathy or coagulopathy; manage per sICH protocol.
Orolingual Angioedema
Incidence and Risk Factors
Orolingual angioedema is an underrecognized complication of thrombolysis, occurring in approximately 1–5% of patients. The primary risk factor is concurrent or recent ACE inhibitor use, which increases risk 3–5 fold. The reaction typically occurs within 30–120 minutes of thrombolytic administration and characteristically involves the contralateral side of the tongue and lips relative to the ischemic hemisphere.
Pathophysiology
The mechanism is predominantly bradykinin-mediated. Plasmin generated by thrombolysis activates the contact system, cleaving high-molecular-weight kininogen to release bradykinin. In patients taking ACE inhibitors, bradykinin degradation is impaired, leading to accumulation and angioedema. A histamine-mediated component may also contribute in some cases, explaining the partial response to antihistamines.
Clinical Presentation
- Swelling of tongue, lips, face, and oropharynx—often contralateral to the stroke hemisphere
- Typically begins within 30–90 minutes of thrombolytic administration
- Can progress rapidly to involve larynx and compromise airway
- More common with alteplase than tenecteplase (longer infusion duration may be a factor)
🔴 Management of Thrombolysis-Associated Angioedema
- Airway assessment: Edema limited to anterior tongue/lips may not require intubation; involvement of larynx, palate, floor of mouth, or oropharynx with rapid progression poses high risk
- Stop alteplase infusion (if still running); hold ACE inhibitors
- Methylprednisolone: 125 mg IV
- Diphenhydramine: 50 mg IV
- H2 blocker: Famotidine 20 mg IV or ranitidine 50 mg IV
- Epinephrine: If worsening, 0.3 mL of 0.1% (1 mg/mL) subcutaneously or 0.5 mL nebulized
- Icatibant: For refractory cases—selective bradykinin B2 receptor antagonist, 30 mg SC; may repeat q6h (max 3 doses/24h)
- C1-esterase inhibitor: 20 IU/kg IV for severe refractory angioedema (used in hereditary angioedema)
- Intubation: Awake fiberoptic intubation preferred if needed; nasotracheal intubation possible but epistaxis risk elevated post-thrombolysis
Other Complications
Systemic Bleeding
Extracranial hemorrhage can occur at any site, with gastrointestinal and genitourinary bleeding being most common. Risk is elevated in patients with recent surgery, trauma, or invasive procedures. Management includes local hemostatic measures, withholding antithrombotics, and reversal agents (cryoprecipitate, TXA) for significant bleeding.
Minor Allergic Reactions
Rash, urticaria, and minor allergic reactions occur in approximately 1–2% of patients. These are typically self-limited and respond to antihistamines. Anaphylaxis is rare but should be managed with standard protocols including epinephrine, airway management, and supportive care.
Hypotension
Transient hypotension may occur during or after thrombolysis, possibly related to reperfusion or underlying cardiac dysfunction. It is usually responsive to fluid resuscitation and rarely requires vasopressors. Persistent hypotension should prompt evaluation for occult bleeding or cardiac causes.
sICH Rates Across Major Thrombolysis Trials
| Trial | Year | Agent | Dose | Window | sICH Rate | Definition |
|---|---|---|---|---|---|---|
| NINDS | 1995 | Alteplase | 0.9 mg/kg | 0–3 h | 6.4% vs 0.6% | NINDS |
| ECASS II | 1998 | Alteplase | 0.9 mg/kg | 0–6 h | 8.8% vs 3.4% | ECASS |
| ECASS III | 2008 | Alteplase | 0.9 mg/kg | 3–4.5 h | 2.4% vs 0.3% | ECASS (NINDS: 7.9%) |
| SITS-MOST | 2007 | Alteplase | 0.9 mg/kg | 0–4.5 h | 1.7% | SITS-MOST |
| ENCHANTED | 2016 | Alteplase | 0.6 vs 0.9 mg/kg | 0–4.5 h | 1.0% vs 2.1% | SITS-MOST |
| NOR-TEST | 2017 | TNK | 0.4 mg/kg | 0–4.5 h | 2.0% vs 2.0% | SITS-MOST |
| EXTEND-IA TNK | 2018 | TNK | 0.25 mg/kg | 0–4.5 h | 1% vs 1% | ECASS II |
| EXTEND | 2019 | Alteplase | 0.9 mg/kg | 4.5–9 h | 6.2% vs 0.9% | SITS-MOST |
| TRACE III | 2024 | TNK | 0.25 mg/kg | 4.5–24 h | 3.0% vs 0.8% | SITS-MOST |
| TIMELESS | 2024 | TNK | 0.25 mg/kg | 4.5–24 h | 3.2% vs 2.3% | Heidelberg |
| MOST | 2024 | Alteplase + adjunct | Standard | 0–3 h | Argatroban 4%, Eptifibatide 3%, Placebo 2% | NINDS |
Conclusion
Complications of IV thrombolysis—while not common—require rapid recognition and protocolized management. Hemorrhagic transformation remains the most feared complication, but understanding the classification systems helps distinguish clinically significant bleeds (PH-2) from benign petechial hemorrhage. Angioedema, though less common, can be life-threatening and is particularly associated with ACE inhibitor use. Cerebral edema management has been refined by negative trials showing no benefit of glibenclamide, hypothermia, or steroids—osmotic therapy and timely decompressive surgery remain the mainstays. A thorough understanding of these complications empowers clinicians to maximize the benefits of thrombolysis while minimizing harm.
References
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587.
- Hacke W, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329. (ECASS III)
- Wahlgren N, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Lancet. 2007;369:275–282.
- Campbell BCV, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–1582. (EXTEND-IA TNK)
- Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2026;57:e00–e00.
- Zhao X, et al. Tenecteplase 4.5 to 24 hours after stroke in patients with large vessel occlusion. Lancet Neurol. 2024. (TRACE III)
- Khatri P, et al. Tenecteplase in large vessel occlusion acute ischemic stroke. JAMA. 2024. (TIMELESS)
- Adeoye O, et al. Adjunctive intravenous argatroban or eptifibatide for ischemic stroke. N Engl J Med. 2024;391:810–820. (MOST)
- Frontera JA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2016;24:6–46.
- Anderson CS, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED). Lancet. 2019;393:877–888.